TITLE

Should CEO grow, then go?

AUTHOR(S)
Hudson, Terese
PUB. DATE
July 1999
SOURCE
H&HN: Hospitals & Health Networks;Jul99, Vol. 73 Issue 7, p24
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents views of chief executive officers David Phelps of Berkshire Health Systems and Greg Lintjer of Elkhart on how a hospital chief executive would decide if he was urged by the board to grow the business with a cancer treatment center. Factors that should be considered by the executive; Reason the project may look like a money loser.
ACCESSION #
2111060

 

Related Articles

  • When cancer strikes. Lauer, Charles S. // Modern Healthcare;6/6/2005, Vol. 35 Issue 23, p24 

    Looks at the story of the battle of Peter Lawson, executive vice president of hospital operations of Health Management Associates and John Hillenmeyer, president and CEO of Orlando Regional Healthcare against cancer. Challenges encountered by Lawson and Hillenmeyer; Impact of cancer treatment...

  • Indevus closer to marketing authorization for Ventas in Europe.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p16 

    The article reports that Indevus Pharmaceuticals Inc. has filed for Mutual Recognition Procedure (MRP) to obtain marketing authorization for Ventas, a subcutaneous implant for the treatment of prostate cancer, in various European countries. Chief executive officer (CEO) Glenn Cooper states the...

  • YM BioSciences gets go-ahead for phase II brain cancer drug trial.  // PharmaWatch: Cancer;Jul2007, Vol. 6 Issue 7, p18 

    The article reports that YM BioSciences Inc. has obtained a clearance from Health Canada to initiate its phase II trial for Nimotuzumab, an experimental drug used to treat patients with recurrent diffuse intrinsic pontine glioma. According to the author, the company is given 18 months to assess...

  • Breaking Through: Renewing Attention to Cancer Pain.  // Pain Community News;Spring2010, Vol. 10 Issue 2, p1 

    The article discusses the breakthrough cancer pains that affect the life of the person diagnosed with cancer. It mentions that this kind of cancer pain interferes the ability to manage other aspects of cancer treatment. According to Will Rowe, American Pain Foundation's chief executive officer,...

  • Precious Mettle. Comer, Benjamin // Pharmaceutical Executive;Jul2011, Vol. 31 Issue 7, p28 

    The article highlights the role of Tony Coles as chief executive officer (CEO) at Onyx Pharmaceuticals Inc. in leading the company to greater heights in the U.S. It recounts how the condition of his son having a compromising mediastinal mass has influenced his craft in discovering new compounds,...

  • Sicel wins reimbursement code for 1st radiation sensor. Yoffee, Lynn // Diagnostics & Imaging Week;5/29/2008, Vol. 11 Issue 22, p1 

    The article reports on the success of Sicel Technologies to get reimbursement code for its Dose Verification System (DVS), a wireless implantable radiation sensor and reader designed to help radiation oncologists determine if the radiation they are administering has hit its target. According to...

  • BIOTECH BLOCKBUSTER. Garcia, Erica // Money;Aug2003, Vol. 32 Issue 8, p48 

    In late June, Arthur Levinson was interviewed by 'MONEY's Erica Garcia in his corner office in south San Francisco, nervously shaking a sneaker-clad foot while awaiting the decision from the Food and Drug Administration on Xolair, Genentech's asthma treatment. Arthur Levinson, the biotech...

  • Amgen 1Q Profit Up 5%; Beats Wall Street Views.  // MondayMorning;4/30/2012, Vol. 20 Issue 18, p1 

    The article informs that Amgen Inc. has released its financial report for the first-quarter of 2012. It states that the net income rose to 1.18 billion U.S. dollars from 1.13 billion U.S. dollars from selling of cancer treatment drugs and generated revenue of 9.2 percent to 4.05 billion U.S....

  • Igenica Raises $24M in Series B to Expand Antibody Platforms. Hollingsworth, Catherine // BioWorld Today;6/11/2010, Vol. 21 Issue 112, p1 

    The article reports on the completion of the 24 million U.S. dollar Series B financing of Igenica Inc., a pharmaceutical biotechnology firm based in Burlingame, California. The financing would enable Igenica to accelerate its efforts discover and develop cancer medicines based on antibodies....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics